Mechanism of action of vitamin E in NAFLD
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA589117 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Mechanism of action of vitamin E in NAFLD
| PRJNA589118 | ENA
Project description:Determine the genetic mechanism of action by which variants near PNPLA3 and LYPLAL1 exert their effects on promoting NAFLD
2018-08-02 | MSV000082692 | GNPS
Project description:Dyslipidemia and inflammation play key roles in the pathogenesis of both nonalcoholic fatty liver disease (NAFLD) and atherosclerosis. NAFLD, particularly its severe form nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular disease (CVD) risk. HDL (high density lipoprotein- also a CVD risk) are decreased in NAFLD but whether HDL function is abnormal in NAFLD is unknown. Furthermore, it is unknown whether dyslipidemia contributes to reduced HDL function in NAFLD and whether hepatic inflammation further impairs HDL function in patients with NASH. Therefore, the aim of this study was to investigate HDL function and to examine the effect of dyslipidemia and inflammation on HDL metabolism in patients with biopsy-proven simple steatosis (SS) and NASH. RESULTS: Compared to controls, SS and NASH subjects had significantly higher levels of plasma triglyceride, insulin, and were more insulin resistant (HOMA, P<0.05) with no differences in total cholesterol, HDL cholesterol, ApoB100 and ApoAI levels. NAFLD patients had increased production and degradation rates of both HDLc and ApoAI that resulted in their levels remaining stable. The degradation rates also were increased of other HDL proteins, including ApoAII, ApoAIV, vitamin D-binding protein, and complement 3 (all P<0.05). NAFLD patients had increased activities of LCAT and CETP, indicating altered HDL lipidation. NAFLD induced alterations in HDL metabolism were associated with reduced anti-oxidant but increased pro-inflammatory activity of HDL. However, no differences were observed in either HDL function or the kinetics of HDLc and HDL proteins between SS and NASH subjects.
2019-08-12 | PXD010199 | Pride
Project description:Liraglutide, a GLP-1 receptor agonist approved for diabetes and obesity, shows promise in treating NAFLD, the most prevalent chronic liver disease globally. Despite its therapeutic potential, the systematic molecular regulations underlying Liraglutide effects on NAFLD remain underexplored, indicating the crucial need to fully understand its mechanism and facilitate its use in NAFLD treatment.Based on this,we established NAFLD modele by feeding C57/BL6 mice a high-fat diet (HFD). After administration of liraglutide injection to HFD mice, liver biochemical parameters were measured to assess the efficacy of liraglutide. Mouse livers were extracted for label-free quantitative proteomics and glycoproteomics analysis to summarize the mechanism of action of liraglutide in ameliorating NAFLD. Meanwhile, liraglutide hydrogels were prepared and characterized to extend the interval of liraglutide injection administration. Our research showed that liraglutide therapeutic effect on NAFLD was largely driven by significant glycosylation changes, which have a more profound impact than changes in overall protein expression. These insights into Liraglutide regulatory networks and targets offered valuable guidance for optimizing NAFLD treatment and advancing its clinical application.
2025-12-15 | PXD055468 | Pride
Project description:The mechanism of action of H4 in the treatment of NAFLD.
2023-01-10 | PXD039354 |
Project description:Vitamin D, in addition to calcium/phosphate metabolism and bone homeostasis regulation, has antiproliferative, anti-inflammatory and antifibrotic properties. These protective actions may have an impact in the progression of chronic liver disease including NAFLD (Non-alcoholic fatty liver disease). Vitamin D deficiency is associated with metabolic syndrome components, such as insulin resistance and dyslipidemia. NAFLD is often considered as the hepatic manifestation of metabolic syndrome, and a growing body of research suggests a relationship between vitamin D deficiency and NAFLD, with low levels of 25(OH)D associated with hepatic inflammation, and the severity and progression of NAFLD.
2022-04-14 | GSE200765 | GEO
Project description:Background: Vitamin D has been observed to affect the expression of a number of genes, however its mechanism of action has not been completely elucidated. MicroRNA molecules have recently been shown to be key mediators of gene regulation. We hypothesised therefore that vitamin D might modulate gene expression by influencing the expression of microRNAs. Methodology/Principal findings: A microRNA array was used to investigate the expression of microRNAs in RNA extracted from cells exposed to calcitriol for 0, 8 or 36 hours. A diverse panel of human cell lines were analysed including Hep-G2, HL60, K562, two fibroblast cell lines (AG09309 and AG09319), and four lymphoblastoid cell lines (GM15084, GM12878, GM07348 and GM07019). When compared between 0, 8 and 36 hours of calcitriol treatment, there were several microRNAs that were differentially regulated but the significance of these was lost after correction for multiple hypothesis testing. Conclusions/Significance: No microRNA showed significantly altered expression after exposure to vitamin D. However, some nominally significant miRNA molecules may warrant further investigation for a potential vitamin D-related role in immune function.
2010-02-02 | GSE20122 | GEO
Project description:AIMS To identify the underlying mechanism by which Vitamin D reduces colorectal cancer risk.
OBJECTIVES To demonstrate the effects of vitamin D supplementation on serum vitamin D levels.
To demonstrate dynamic changes in gene expression in response to vitamin D. To demonstrate the mechanism underlying the gene-environment interaction of vitamin D, susceptibility genetic variants (risk genes) and colorectal cancer.
| 2376099 | ecrin-mdr-crc
Project description:Investigation of the Mechanism of Action by Comprehensive Transcriptome Analysis
| PRJNA1007669 | ENA